GeneDx Holdings Statistics
Total Valuation
GeneDx Holdings has a market cap or net worth of $1.72 billion. The enterprise value is $1.72 billion.
| Market Cap | 1.72B |
| Enterprise Value | 1.72B |
Important Dates
The next estimated earnings date is Tuesday, July 28, 2026, before market open.
| Earnings Date | Jul 28, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
GeneDx Holdings has 29.69 million shares outstanding. The number of shares has increased by 5.57% in one year.
| Current Share Class | 29.69M |
| Shares Outstanding | 29.69M |
| Shares Change (YoY) | +5.57% |
| Shares Change (QoQ) | +0.98% |
| Owned by Insiders (%) | 2.90% |
| Owned by Institutions (%) | 91.80% |
| Float | 18.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 140.22 |
| PS Ratio | 3.90 |
| Forward PS | 3.42 |
| PB Ratio | 6.78 |
| P/TBV Ratio | 16.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 3.89 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.09, with a Debt / Equity ratio of 0.66.
| Current Ratio | 3.09 |
| Quick Ratio | 2.83 |
| Debt / Equity | 0.66 |
| Debt / EBITDA | 364.84 |
| Debt / FCF | n/a |
| Interest Coverage | -12.73 |
Financial Efficiency
Return on equity (ROE) is -30.42% and return on invested capital (ROIC) is -13.28%.
| Return on Equity (ROE) | -30.42% |
| Return on Assets (ROA) | -4.37% |
| Return on Invested Capital (ROIC) | -13.28% |
| Return on Capital Employed (ROCE) | -7.96% |
| Weighted Average Cost of Capital (WACC) | 13.85% |
| Revenue Per Employee | $340,522 |
| Profits Per Employee | -$59,852 |
| Employee Count | 1,300 |
| Asset Turnover | 0.93 |
| Inventory Turnover | 10.82 |
Taxes
In the past 12 months, GeneDx Holdings has paid $334,000 in taxes.
| Income Tax | 334,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -13.31% in the last 52 weeks. The beta is 1.97, so GeneDx Holdings's price volatility has been higher than the market average.
| Beta (5Y) | 1.97 |
| 52-Week Price Change | -13.31% |
| 50-Day Moving Average | 54.67 |
| 200-Day Moving Average | 98.70 |
| Relative Strength Index (RSI) | 54.66 |
| Average Volume (20 Days) | 1,141,821 |
Short Selling Information
The latest short interest is 4.57 million, so 15.40% of the outstanding shares have been sold short.
| Short Interest | 4.57M |
| Short Previous Month | 4.93M |
| Short % of Shares Out | 15.40% |
| Short % of Float | 24.56% |
| Short Ratio (days to cover) | 2.17 |
Income Statement
In the last 12 months, GeneDx Holdings had revenue of $442.68 million and -$77.81 million in losses. Loss per share was -$2.69.
| Revenue | 442.68M |
| Gross Profit | 307.91M |
| Operating Income | -33.31M |
| Pretax Income | -77.47M |
| Net Income | -77.81M |
| EBITDA | -7.85M |
| EBIT | -33.31M |
| Loss Per Share | -$2.69 |
Balance Sheet
The company has $170.69 million in cash and $168.19 million in debt, with a net cash position of $2.49 million or $0.08 per share.
| Cash & Cash Equivalents | 170.69M |
| Total Debt | 168.19M |
| Net Cash | 2.49M |
| Net Cash Per Share | $0.08 |
| Equity (Book Value) | 254.12M |
| Book Value Per Share | 8.57 |
| Working Capital | 182.99M |
Cash Flow
In the last 12 months, operating cash flow was -$9.31 million and capital expenditures -$19.34 million, giving a free cash flow of -$28.65 million.
| Operating Cash Flow | -9.31M |
| Capital Expenditures | -19.34M |
| Depreciation & Amortization | 25.46M |
| Net Borrowing | 21.41M |
| Free Cash Flow | -28.65M |
| FCF Per Share | -$0.97 |
Margins
Gross margin is 69.56%, with operating and profit margins of -7.52% and -17.58%.
| Gross Margin | 69.56% |
| Operating Margin | -7.52% |
| Pretax Margin | -17.50% |
| Profit Margin | -17.58% |
| EBITDA Margin | -1.77% |
| EBIT Margin | -7.52% |
| FCF Margin | n/a |
Dividends & Yields
GeneDx Holdings does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -5.57% |
| Shareholder Yield | -5.57% |
| Earnings Yield | -4.51% |
| FCF Yield | -1.66% |
Analyst Forecast
The average price target for GeneDx Holdings is $78.44, which is 35.06% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $78.44 |
| Price Target Difference | 35.06% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | 19.70% |
| EPS Growth Forecast (3Y) | 9.54% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 4, 2023. It was a reverse split with a ratio of 1:33.
| Last Split Date | May 4, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:33 |
Scores
GeneDx Holdings has an Altman Z-Score of 4.26 and a Piotroski F-Score of 3.
| Altman Z-Score | 4.26 |
| Piotroski F-Score | 3 |